Birchler Brian 4
4 · IONIS PHARMACEUTICALS INC · Filed Oct 16, 2025
Insider Transaction Report
Form 4
Birchler Brian
EVP, Corp and Development Ops
Transactions
- Sale
Common Stock
2025-10-14$72.03/sh−11,475$826,589→ 56,826 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-14−11,475→ 12,425 totalExercise: $53.77From: 2020-01-02Exp: 2026-01-01→ Common Stock (11,475 underlying) - Exercise/Conversion
Common Stock
2025-10-15$53.77/sh+12,425$668,092→ 69,251 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-15−12,425→ 0 totalExercise: $53.77From: 2021-01-02Exp: 2026-01-01→ Common Stock (12,425 underlying) - Exercise/Conversion
Common Stock
2025-10-14$53.77/sh+11,475$617,011→ 68,301 total - Sale
Common Stock
2025-10-15$72.23/sh−12,425$897,398→ 56,826 total
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 12, 2024.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.115, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.46, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.